Tonix Pharmaceuticals Holding Investor Presentation — September 2017 - Tonix Pharmaceuticals Holding Corp.

Document content

Version P0077 9-8 -17 (Doc 0272)

Investor Presentation

Cautionary Note on Forward

Certain statements inthispresentation regarding strategic plans, expectations andobjectives forfuture

operations orresults are“forward -looking statements” asdefined bythePrivate Securities Litigation Reform

Actof1995.These statements may beidentified bytheuseofforward -looking words such as“anticipate,”

“believe,” “forecast,” “estimate” and“intend,” among others .These forward -looking statements arebased on

Tonix’s current expectations andactual results could differ materially .There areanumber offactors that

could cause actual events todiffer materially from those indicated bysuch forward -looking statements. These

factors include, butarenotlimited to,substantial competition ;ourneed foradditional financing ;uncertainties

ofpatent protection andlitigation ;uncertainties ofgovernment orthird party payor reimbursement ;limited

research anddevelopment efforts anddependence upon third parties ;andrisks related tofailure toobtain

U.S.Food andDrug Administration clearances orapprovals andnoncompliance withitsregulations .Aswith

anypharmaceutical under development, there aresignificant risks inthedevelopment, regulatory approval

andcommercialization ofnewproducts .Theforward -looking statements inthispresentation aremade asof

thedateofthispresentation, even ifsubsequently made available byTonix onitswebsite orotherwise .Tonix

does notundertake anobligation toupdate orrevise anyforward -looking statement, except asrequired by

law.Investors should read theriskfactors setforth intheAnnual Report onForm 10-Kfortheyear ended

December 31,2016, asfiledwiththeSecurities andExchange Commission (the“SEC”) onApril13,2017,and

future periodic reports filedwiththeSEConorafter thedatehereof .AllofTonix's forward -looking statements

(Cyclobenzaprine HCl Sublingual

for Posttraumatic Stress Disorder (PTSD)

Phase 3 HONOR study of Tonmya1in military -related PTSD enrolling

•Encouraging evidence of safety and efficacy was demonstrated in Phase 2

Breakthrough Therapy designation from U.S. Food and Drug Administration (FDA)

•Expedited development and accelerated review are expected

•Potential to file NDA2based on one Phase 3 study if data are statistically persuasive